BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)

September 09, 2021

BioCardia®, Inc. (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand  at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference.  The conference is being held as a virtual conference on September 13-15, 2021.

Dr. Peter Altman, CEO of BioCardia, will be participating in one-on-one meetings at the conference.  If you are an institutional or retail investor, and would like to listen to the Company’s presentation and/or request a 1:1 meeting with BioCardia management, please click on the following link ( to register for the conference. 

Event:  H.C. Wainwright 23rd Annual Global Investment Conference (Virtual Conference)

Dates:  September 13-15, 2021

Time:  Company presentation on demand starting at 7am (Eastern Time)

Location:  Virtual Conference


About BioCardia®

BioCardia, Inc., headquartered in San Carlos, California, is a developer of two biotherapeutic platforms – the CardiAMPTM autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases.  These platforms underly four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Company’s proprietary biotherapeutic delivery platforms, which the Company also selectively licenses to other biotherapeutic development firms.  For more information, visit


Have questions?
: (800) 624-1179
Have questions?

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.